ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 1670 • ACR Convergence 2022

    Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma

    Noha Abdel-Wahab1, Emma J. Montazari1, Christine A. Spillson1, Salah-Eddine Bentebibel1, Jean H. Tayar1, Maria Suarez-Almazor2, Suhendan Ekmekcioglu1, Daniel H. Johnson3 and Adi Diab1, 1UT MD Anderson Cancer Center, Houston, TX, 2MD Anderson Cancer Center, Houston, TX, 3Ochsner Health, New Orleans, LA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) led to impressive survival benefits in treatment of cancers. However, immune-related adverse events (irAEs) can cause treatment discontinuation and sometimes…
  • Abstract Number: 1904 • ACR Convergence 2022

    Is Treating Painful Hand Osteoarthritis with Hormone Replacement Therapy Feasible? Primary Results from a Randomised Controlled Trial in Post-menopausal Women

    Jennifer Williams1, Mae Chester-Jones1, Megan Goff2, Anne Francis1, Gretchen Brewer1, Ioana Marian1, Malvika Gulati1, Charles Mackworth-Young3, Victoria Glover4, Sarah Lamb1, Tonia Vincent5, Katy Vincent1, Susan Dutton1 and Fiona Watt6, 1University of Oxford, Oxford, United Kingdom, 2University of Oxford, London, United Kingdom, 3Imperial College Healthcare NHS Trust, London, United Kingdom, 4White Horse Medical Practice, Faringdon, United Kingdom, 5Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 6Imperial College London, London, United Kingdom

    Background/Purpose: Hand osteoarthritis (OA) is more common in females and relative risk increases further around the age of menopause, potentially implicating sex hormone deficiency. There…
  • Abstract Number: 2112 • ACR Convergence 2022

    Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Christopher Ritchlin1, Philip J Mease2, Wolf-Henning Boehncke3, John Tesser4, Soumya Chakravarty5, Emmanouil Rampakakis6, May Shawi7, Elena Schiopu8, Joseph Merola9, Iain B McInnes10 and Atul Deodhar11, 1Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, 4Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 5Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
  • Abstract Number: 0292 • ACR Convergence 2022

    Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Andrea Rubbert-Roth1, Adriana Kakehasi2, Tsutomu Takeuchi3, Marc Schmalzing4, Hannah Palac5, Jianzhong Liu5, Samuel Anyanwu5, Ralph Lippe6 and Jeffrey Curtis7, 1Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 2Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, 3Keio University and Saitama Medical University, Tokyo, Japan, 4University Hospital Wuerzburg, Wuerzburg, Germany, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc, Wiesbaden, Germany, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
  • Abstract Number: 0364 • ACR Convergence 2022

    Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)

    Richard Furie1, Ronald van Vollenhoven2, Victoria Werth3, Kenneth Kalunian4, Sandra Navarra5, Juanita Romero-Diaz6, Ting Wang7, Cristina Musselli7, Catherine Barbey8 and Nathalie Franchimont7, 1Northwell Health, Great Neck, NY, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 4University of California San Diego, La Jolla, CA, 5University of Santo Tomas, Manila, Philippines, 6Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 7Biogen, Cambridge, MA, 8Biogen, Baar, Switzerland

    Background/Purpose: SLE is a heterogeneous illness that often manifests with skin and/or joint diseases.1 BIIB059 is a humanized monoclonal antibody that binds to BDCA2, a…
  • Abstract Number: 0530 • ACR Convergence 2022

    Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

    Juergen Rech1, Arnd Kleyer2, Mikkel Østergaard3, Melanie Hagen2, Larissa Valor Mendez2, Koray Tascilar2, Gerhard Kroenke2, Verena Schönau2, David Simon2, stefan Kleinert4, Xenofon Baraliakos5, Juergen Braun6, Axel Hueber7, Martin Fleck8, Andrea Rubbert-Roth9, Frank Behrens10, Martin Feuchtenberger11, M. Zaenker12, Reinhard Voll13, Cornelia Glaser14, Mária Filková15, Eugen Feist16, Gerd Burmester17, Kirsten Karberg18, Johannes Strunk19, Juan Canete20, Ladislav Šenolt15, Esperanza Naredo21 and Georg Schett22, 1University Clinic Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 4Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 5Ruhr University Bochum, Department of Rheumatology, Bochum, Germany; Rheumazentrum Ruhrgebiet, Rheumazentrum Ruhrgebiet, Herne, Germany, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Klinikum Nuernberg Nord, Abteilung fuer Rheumatologie, Nuernberg, Germany, 8Asklepios Klinikum Bad Abbach, Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, 9Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 10Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, 11MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, 12Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, 13Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg im Breisgau, Germany, 14Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 15Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 16Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, 17Charité University Medicine Berlin, Berlin, Germany, 18Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, 19Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Koeln, Germany, 20Unidad de Artritis Hospital Clinic, Barcelona, Spain, 21Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, 22Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…
  • Abstract Number: 1001 • ACR Convergence 2022

    Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)

    David Isenberg1, Celia Lin2, Amy Kao3, Aida Aydemir4 and Caroline Gordon5, 1University College London, London, United Kingdom, 2Vera Therapeutics, Inc, Burlingame, CA, 3EMD Serono, Billerica, MA, 4EMD Serono Research & Development Institute, Inc, Billerica, MA, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…
  • Abstract Number: 1509 • ACR Convergence 2022

    Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations

    Xenofon Baraliakos1, Effie Pournara2, Dafna Gladman3, Philip J Mease4, Samad S Jahandideh2 and Laura Coates5, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 4Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…
  • Abstract Number: 1675 • ACR Convergence 2022

    Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial

    Stephen Messier1, Daniel Beavers2, Kate Queen3, Shannon Mihalko1, Gary Miller1, Elena Losina4, Jeffrey Katz4, Richard Loeser5, Paul DeVita6, David Hunter7, Jovita Newman1, Sara Quandt8, Mary Lyles2, Joanne Jordan9 and Leigh Callahan10, 1Wake Forest University, Winston-Salem, NC, 2Wake Forest University School of Medicine, Winston-Salem, NC, 3Haywood Regional Medical Center, Waynesville, NC, 4Brigham and Women's Hospital, Boston, MA, 5University of North Carolina, Chapel Hill, NC, 6East Carolina University, Greenville, NC, 7University of Sydney, Sydney, Australia, 8Wake Forest School of Medicine, Winston-Salem, NC, 9University of North Carolina School of Medicine, Chapel Hill, NC, 10University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

    Background/Purpose: Many health systems that treat people with knee osteoarthritis (OA) have no infrastructure in place to implement weight loss and exercise treatments. The policy…
  • Abstract Number: 1909 • ACR Convergence 2022

    Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol

    Grégoire Cormier1, Amelie Denis2, CHARLES LESKE3, Stephane Varin1, Jerome Dimet4, Lucie Planche1 and Benoit Le Goff5, 1CHD Vendee, La Roche Sur Yon, France, 2CH Le Mans, Le Mans, France, 3Hospital, Cholet, France, 4CH Mont de Marsan, Mont de Marsan, France, 5CHU Nantes, Nantes, France

    Background/Purpose: Trapeziometacarpal osteoarthritis is highly prevalent (affects 10 to 25% of people). Treatment modalities consist of non-pharmacological and pharmacological measures, including either corticosteroid or hyaluronic…
  • Abstract Number: 2113 • ACR Convergence 2022

    Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

    Dennis McGonagle1, Derek Haaland2, Philip Helliwell3, A. Marilise Marrache4, May Shawi5, Emmanouil Rampakakis6, Peter Nash7, Fedra Irazoque Palazuelos8 and Arthur Kavanaugh9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2The Waterside Clinic, Oro Medonte, ON, Canada, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7School of Medicine, Griffith University, Sunshine Coast, Australia, 8Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, 9University of California San Diego, La Jolla, CA

    Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
  • Abstract Number: 0293 • ACR Convergence 2022

    Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND

    Ronald van Vollenhoven1, Stephen Hall2, Alvin Wells3, Sebastian Meerwein4, Yanna Song5, Jessica Suboticki6 and Roy Fleischmann7, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Emeritus Research and Monash University, Melbourne, Australia, 3Aurora Rheumatology and Immunotherapy Center, Franklin, WI, 4AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
  • Abstract Number: 0365 • ACR Convergence 2022

    Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)

    Victoria Werth1, Ronald van Vollenhoven2, Richard Furie3, Filippa Nyberg4, Kenneth Kalunian5, Sandra Navarra6, Juanita Romero-Diaz7, Wenbin Zhu8, Catherine Barbey9, Cristina Musselli8 and Nathalie Franchimont8, 1University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Northwell Health, Great Neck, NY, 4Karolinska University Hospital, Stockholm, Sweden, 5University of California San Diego, La Jolla, CA, 6University of Santo Tomas, Manila, Philippines, 7Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 8Biogen, Cambridge, MA, 9Biogen, Baar, Switzerland

    Background/Purpose: BIIB059 is a humanized monoclonal antibody against BDCA2, a receptor exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of cutaneous…
  • Abstract Number: 0543 • ACR Convergence 2022

    An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis

    Martin Rudwaleit1, Filip Van den bosch2, Helena Marzo-Ortega3, Victoria Navarro-Compán4, Rachel Tham5, Thomas Kumke6, Lars Bauer6, Mindy Kim7 and Lianne Gensler8, 1University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 2Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 3Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5UCB Pharma, Slough, UK, Overland Park, KS, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Smyrna, GA, 8Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: In clinical trials of axial spondyloarthritis (axSpA), composite measures such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response criteria, Assessment of Spondyloarthritis international…
  • Abstract Number: 1002 • ACR Convergence 2022

    Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod

    Daniel Strasser1, clélia Cahuzac2, peter Cornelisse2, Ouali Berkani2, Peter Groenen2 and Mark Murphy2, 1Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, 2Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland

    Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs into circulation. In a SLE proof-of-concept study, cenerimod—a potent, selective S1P1 receptor modulator—reduced circulating antibody-secreting cells…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology